{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:44:50Z","timestamp":1794242690321,"version":"4.9.0"},"reference-count":94,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Dyslipidaemia remains a major contributor to cardiovascular morbidity and mortality, despite the availability of effective lipid-lowering therapies and well-established European Society of Cardiology\/European Atherosclerosis Society guidelines. In clinical practice, the implementation of these recommendations is often suboptimal, with persistent therapeutic inertia and fragmented decision-making processes. The CARDIOLIPID Plan is a proposed cardiovascular risk-centred implementation framework designed to support the practical application of guideline-based care. The model integrates two key components of clinical decision-making: comprehensive cardiovascular risk assessment (CARDIO) and personalised lipid-lowering intervention (LIPID), structured into a sequential and clinically applicable pathway. While the individual elements of the CARDIOLIPID Plan are derived from current evidence and guideline recommendations, their organisation within this framework reflects an interpretation by experts aimed at improving clarity, usability and clinical implementation. The model emphasises early and appropriate treatment intensification, reduction of therapeutic inertia and a holistic, patient-centred approach to cardiovascular risk management. The CARDIOLIPID Plan may serve as a practical tool to enhance the translation of evidence into clinical practice. However, as a conceptual and implementation-oriented framework, it requires validation in real-world settings to assess its impact on treatment outcomes and cardiovascular risk reduction.<\/jats:p>","DOI":"10.15420\/ecr.2026.08","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:20:46Z","timestamp":1783534846000},"source":"Crossref","is-referenced-by-count":3,"title":["The CARDIOLIPID Plan: A Cardiovascular Risk-centred Implementation Framework for the Diagnosis and Management of Dyslipidaemia: Experts\u2019 Proposal"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-6664","authenticated-orcid":false,"given":"Stanis\u0142aw","family":"Surma","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/005k7hp45","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical University of Silesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9724","authenticated-orcid":false,"given":"Marcin","family":"Barylski","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02t4ekc95","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical University of Lodz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-5883","authenticated-orcid":false,"given":"Roland E","family":"Schmieder","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0030f2a11","id-type":"ROR","asserted-by":"publisher"}],"name":"Universit\u00e4tsklinikum Erlangen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8433-4723","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Bologna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-3176","authenticated-orcid":false,"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ynf4891","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Milano-Bicocca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory YH","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-0877","authenticated-orcid":false,"given":"Krzysztof J","family":"Filipiak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00y4ya841","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical University of Bia\u0142ystok"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Uchmanowicz I, Czapla M, Lomper K, et al. Effective implementation of preventive cardiology guidelines: pathways to success. Eur J Prev Cardiol 2025:zwaf448. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf448; PMID:\u00a040680090.","DOI":"10.1093\/eurjpc\/zwaf448"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Almahmeed W, Alabadla Z, Al Awadi F, et al. Improving therapeutic adherence and reducing therapeutic inertia in the management of people with cardiometabolic diseases: a call-to-action from the Middle East. Adv Ther 2025;42:1340\u201359. https:\/\/doi.org\/10.1007\/s12325-024-03103-5; PMID:\u00a039841371.","DOI":"10.1007\/s12325-024-03103-5"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Dixon DL, Sharma G, Sandesara PB, et al. Therapeutic inertia in cardiovascular\u00a0disease prevention: time to move the bar. J Am Coll Cardiol 2019;74:1728\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.014; PMID:\u00a031558257.","DOI":"10.1016\/j.jacc.2019.08.014"},{"key":"ref3","unstructured":"Kreutz R, Brunstr\u00f6m M, Burnier M, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med 2024;126:1\u201315. https:\/\/doi.org\/10.1016\/j.ejim.2024.05.033; PMID:\u00a038914505."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Chao TF, Potpara TS, Lip GYH. Atrial fibrillation: stroke prevention. Lancet Reg Health Eur 2024;37:100797. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100797; PMID:\u00a038362551.","DOI":"10.1016\/j.lanepe.2023.100797"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Banach M, Surma S, Guzik TJ, et al. Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention. Cardiovasc Res 2025;121:851\u20139. https:\/\/doi.org\/10.1093\/cvr\/cvaf045; PMID:\u00a040098223.","DOI":"10.1093\/cvr\/cvaf045"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"We\u0142nicki M, Gorczyca-G\u0142owacka I, Kap\u0142on-Cie\u015blicka A, et al. Treatment of dyslipidemia in Poland \u2013 common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot. Cardiol J 2025;32:107\u201319. https:\/\/doi.org\/10.5603\/cj.103680; PMID:\u00a040162986.","DOI":"10.5603\/cj.103680"},{"key":"ref7","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010; PMID:\u00a033309175."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, et al. The global syndemic of modifiable cardiovascular risk factors projected from 2025 to 2050. J Am Coll Cardiol 2025;86:165\u201377. https:\/\/doi.org\/10.1016\/j.jacc.2025.04.061; PMID:\u00a040669954.","DOI":"10.1016\/j.jacc.2025.04.061"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Bueno R, N\u00fa\u00f1ez-Cort\u00e9s R, Calatayud J, et al. Global prevalence of cardiovascular risk factors based on the Life\u2019s Essential 8 score: an overview of systematic reviews and meta-analysis. Cardiovasc Res 2024;120:13\u201333. https:\/\/doi.org\/10.1093\/cvr\/cvad176; PMID:\u00a038033266.","DOI":"10.1093\/cvr\/cvad176"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990\u20132023. J Am Coll Cardiol 2025;86:2167\u2013243. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.015. PMID:\u00a040990886.","DOI":"10.1016\/j.jacc.2025.08.015"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J 2019;210:18\u201328. https:\/\/doi.org\/10.1016\/j.ahj.2018.12.007; PMID:\u00a030716508.","DOI":"10.1016\/j.ahj.2018.12.007"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ma W, Pan Q, Pan D, et al. Efficacy and safety of lipid-lowering drugs of different intensity on clinical outcomes: a systematic review and network meta-analysis. Front Pharmacol 2021;12:713007. https:\/\/doi.org\/10.3389\/fphar.2021.713007; PMID:\u00a034744709.","DOI":"10.3389\/fphar.2021.713007"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Baigent C, Keech A, Kearney PM, et al.. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(05)67394-1; PMID:\u00a016214597.","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018;15:757\u201369. https:\/\/doi.org\/10.1038\/s41569-018-0098-5; PMID:\u00a030375494.","DOI":"10.1038\/s41569-018-0098-5"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Patti G, Spinoni EG, Grisafi L, et al. Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials. Eur Heart J Cardiovasc Pharmacother 2023;9:138\u201347. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac049; PMID:\u00a036102667.","DOI":"10.1093\/ehjcvp\/pvac049"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013;6:390\u20139. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.111.000071; PMID:\u00a023838105.","DOI":"10.1161\/CIRCOUTCOMES.111.000071"},{"key":"ref17","unstructured":"Ray KK, Aguiar C, Arca M, et al. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol 2024;31:1792\u2013803. https:\/\/doi.org\/10.1093\/eurjpc\/zwae199; PMID:\u00a038861400."},{"key":"ref18","unstructured":"De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019;285:135\u201346. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.03.014; PMID:\u00a031054483."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Seo YH, Hong JY, Kim YK, et al. Therapeutic inertia in statin therapy for secondary prevention after percutaneous coronary intervention: a nationwide population-based cohort study. BMC Cardiovasc Disord 2025;25:595. https:\/\/doi.org\/10.1186\/s12872-025-05081-0; PMID:\u00a040783721.","DOI":"10.1186\/s12872-025-05081-0"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Holthuis EI, Visseren FLJ, Bots ML, et al. Risk factor clusters and cardiovascular disease in high-risk patients: the UCC-SMART study. Glob Heart 2021;16:85. https:\/\/doi.org\/10.5334\/gh.897; PMID:\u00a035141126.","DOI":"10.5334\/gh.897"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1012848; PMID:\u00a022276822.","DOI":"10.1056\/NEJMoa1012848"},{"key":"ref22","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455; PMID:\u00a031504418."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025;46:4359\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190; PMID:\u00a040878289.","DOI":"10.1093\/eurheartj\/ehaf919"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kurpas D, Petrazzuoli F, Shantsila E, et al. Implementation of prevention guidelines in primary healthcare: a scientific statement of the European Association of Preventive Cardiology of the ESC, the ESC Council for Cardiology Practice, the Association of Cardiovascular Nursing & Allied Professions of the ESC, WONCA Europe, and EURIPA. Eur J Prev Cardiol 2025:zwaf384. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf384; PMID:\u00a040673363.","DOI":"10.1093\/eurjpc\/zwaf384"},{"key":"ref25","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484; PMID:\u00a034458905."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Csenteri O, Jancs\u00f3 Z, Sz\u00f6ll\u00f6si GJ, et al. Differences of cardiovascular risk assessment in clinical practice using SCORE and SCORE2. Open Heart 2022;9:e002087. https:\/\/doi.org\/10.1136\/openhrt-2022-002087; PMID:\u00a036442905.","DOI":"10.1136\/openhrt-2022-002087"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Rabiee Rad M, Ghasempour Dabaghi G, Darouei B, Amani-Beni R. The association of atherogenic index of plasma with cardiovascular outcomes in patients with coronary artery disease:\u00a0a systematic review and meta-analysis. Cardiovasc Diabetol 2024;23:119. https:\/\/doi.org\/10.1186\/s12933-024-02198-y; PMID:\u00a038566139.","DOI":"10.1186\/s12933-024-02198-y"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Banach M, Reiner \u017d, Surma S, et al. 2024 Recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the international lipid expert panel (ILEP). Drugs 2024;84:1541\u201377. https:\/\/doi.org\/10.1007\/s40265-024-02105-5; PMID:\u00a039497020.","DOI":"10.1007\/s40265-024-02105-5"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion series. J Am Coll Cardiol 2018;72:1141\u201356. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.046; PMID:\u00a030165986.","DOI":"10.1016\/j.jacc.2018.06.046"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Surma S, Lewek J, Penson PE, Banach M. Statin intolerance: an overview for clinicians. In: Jenkins AJ, Toth PP, eds. Lipoproteins in Diabetes Mellitus. Cham: Springer Intl, 2023;597\u2013635. https:\/\/doi.org\/10.1007\/978-3-031-26681-2_23.","DOI":"10.1007\/978-3-031-26681-2_23"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337\u201345. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.110.959247; PMID:\u00a021487090.","DOI":"10.1161\/CIRCOUTCOMES.110.959247"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Superko H, Garrett B. Small dense LDL: Scientific background, clinical relevance, and recent evidence still a risk even with \u2018normal\u2019 LDL-C levels. Biomedicines 2022;10:829. https:\/\/doi.org\/10.3390\/biomedicines10040829; PMID:\u00a035453579.","DOI":"10.3390\/biomedicines10040829"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: discriminant ratio and unbiased equivalence. Cardiovasc Diabetol 2011;10:20. https:\/\/doi.org\/10.1186\/1475-2840-10-20; PMID:\u00a021356116.","DOI":"10.1186\/1475-2840-10-20"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Surma S, Sosnowska B, Reiner \u017d, Banach M. New data allow to better understand the secrets of lipoprotein(a): is that for sure? Eur Heart J Open 2024;4:oeae066. https:\/\/doi.org\/10.1093\/ehjopen\/oeae066; PMID:\u00a039219853.","DOI":"10.1093\/ehjopen\/oeae066"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Surma S, Zembala MO, Okopie\u0144 B, Banach M. Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation. Int J Cardiol CardioVasc Risk Prev 2024;22:200297. https:\/\/doi.org\/10.1016\/j.ijcrp.2024.200297; PMID:\u00a038962113.","DOI":"10.1016\/j.ijcrp.2024.200297"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Franczyk B, M\u0142ynarska E, Rysz-G\u00f3rzy\u0144ska M, et al. High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels. Am J Prev Cardiol 2025;23:101068. https:\/\/doi.org\/10.1016\/j.ajpc.2025.101068; PMID:\u00a040787436.","DOI":"10.1016\/j.ajpc.2025.101068"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Gluba-Sagr A, Olszewski R, Franczyk B, et al. High-density lipoproteins. Part 2. Impact of disease states on functionality. Am J Prev Cardiol 2025;23:101073. https:\/\/doi.org\/10.1016\/j.ajpc.2025.101073; PMID:\u00a040894318.","DOI":"10.1016\/j.ajpc.2025.101073"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Schuitema PCE, Visseren FLJ, Nordestgaard BG, et al. Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease. Atherosclerosis 2025;408:120411. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120411; PMID:\u00a040579281.","DOI":"10.1016\/j.atherosclerosis.2025.120411"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Santos RD, Gidding SS, Bourbon M, et al. Recent advances in research and care of familial hypercholesterolaemia. Lancet Diabetes Endocrinol 2025;13:1054\u201371. https:\/\/doi.org\/10.1016\/S2213-8587(25)00286-4; PMID:\u00a041138742.","DOI":"10.1016\/S2213-8587(25)00286-4"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"My\u015bliwiec M, Bandura M, Wo\u0142oszyn-Durkiewicz A, et al. 2024 Polish recommendations for the management of familial hypercholesterolemia in children and adolescents. Arch Med Sci 2024;20:1741\u201353. https:\/\/doi.org\/10.5114\/aoms\/196329; PMID:\u00a039967943.","DOI":"10.5114\/aoms\/196329"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Tokgozoglu L, Kayikcioglu M. Familial hypercholesterolemia: global burden and approaches. Curr Cardiol Rep 2021;23:151. https:\/\/doi.org\/10.1007\/s11886-021-01565-5; PMID:\u00a034480646.","DOI":"10.1007\/s11886-021-01565-5"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Singh A, Gupta A, Collins BL, et al. Familial hypercholesterolemia among young adults with myocardial infarction. J Am Coll Cardiol 2019;73:2439\u201350. https:\/\/doi.org\/10.1016\/j.jacc.2019.02.059; PMID:\u00a031097165.","DOI":"10.1016\/j.jacc.2019.02.059"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Surma S, Lip GYH. Periodontitis and atrial fibrillation. Eur J Prev Cardiol 2025:zwaf626. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf626; PMID:\u00a041061679.","DOI":"10.1093\/eurjpc\/zwaf626"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Surma S, Roma\u0144czyk M, Witali\u0144ska-\u0141abuzek J, et al. Periodontitis, blood pressure, and the risk and control of arterial hypertension: epidemiological, clinical, and pathophysiological aspects-review of the literature and clinical trials. Curr Hypertens Rep 2021;23:27. https:\/\/doi.org\/10.1007\/s11906-021-01140-x; PMID:\u00a033961166.","DOI":"10.1007\/s11906-021-01140-x"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Czerniuk MR, Surma S, Roma\u0144czyk M, et al. Unexpected relationships: periodontal diseases: atherosclerosis-plaque destabilization? From the teeth to a coronary event. Biology (Basel) 2022;11:272. https:\/\/doi.org\/10.3390\/biology11020272; PMID:\u00a035205138.","DOI":"10.3390\/biology11020272"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Papadopoulou AM, Marinou A. Rhinosinusitis and stroke: a systematic review. Cureus 2023;15:e40923. https:\/\/doi.org\/10.7759\/cureus.40923; PMID:\u00a037496556.","DOI":"10.7759\/cureus.40923"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Styczkiewicz K, Lewicka E, Bielecka-D\u0105browa A, et al. Principles of primary prevention of cardiovascular diseases in patients with cancer. Expert opinion of the Working Group on Prevention and Epidemiology (Cardio-Oncology Task Force) and the Working Group on Cardio-Oncology of the Polish Cardiac Society. Kardiol Pol 2026;84:131\u201356. https:\/\/doi.org\/10.33963\/v.phj.109247; PMID:\u00a041496640.","DOI":"10.33963\/v.phj.109247"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Won H, Bae JH, Lim H, et al. 2024 KSoLA consensus on secondary dyslipidemia. J Lipid Atheroscler 2024;13:215\u201331. https:\/\/doi.org\/10.12997\/jla.2024.13.3.215; PMID:\u00a039355405.","DOI":"10.12997\/jla.2024.13.3.215"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Luca AC, David SG, David AG, et al. Atherosclerosis from newborn to adult-epidemiology, pathological aspects, and risk factors. Life (Basel) 2023;13:2056. https:\/\/doi.org\/10.3390\/life13102056; PMID:\u00a037895437.","DOI":"10.3390\/life13102056"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Friera L, Pe\u00f1alvo JL, Fern\u00e1ndez-Ortiz A, et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (progression of early subclinical atherosclerosis) study. Circulation 2015;131:2104\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014310; PMID:\u00a025882487.","DOI":"10.1161\/CIRCULATIONAHA.114.014310"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Fuster V, Garc\u00eda-\u00c1lvarez A, Devesa A, et al. Influence of subclinical atherosclerosis burden and progression on mortality. J Am Coll Cardiol 2024;84:1391\u2013403. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.045; PMID:\u00a039357937.","DOI":"10.1016\/j.jacc.2024.06.045"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Migrino RQ, Bowers M, Harmann L, et al. Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. J Cardiovasc Magn Reson 2011;13:37. https:\/\/doi.org\/10.1186\/1532-429X-13-37; PMID:\u00a021812992.","DOI":"10.1186\/1532-429X-13-37"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012;308:788\u201395. https:\/\/doi.org\/10.1001\/jama.2012.9624; PMID:\u00a022910756.","DOI":"10.1001\/jama.2012.9624"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Blaha MJ, DeFilippis AP. Multi-ethnic study of atherosclerosis (MESA): JACC focus Seminar 5\/8. J Am Coll Cardiol 2021;77:3195\u2013216. https:\/\/doi.org\/10.1016\/j.jacc.2021.05.006; PMID:\u00a034167645.","DOI":"10.1016\/j.jacc.2021.05.006"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association. J Clin Lipidol 2023;17:428\u201351. https:\/\/doi.org\/10.1016\/j.jacl.2023.05.099; PMID:\u00a037271600.","DOI":"10.1016\/j.jacl.2023.05.099"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Surma S, Sahebkar A, Banach M. Coffee or tea: anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention. Pharmacol Res 2023;187:106596. https:\/\/doi.org\/10.1016\/j.phrs.2022.106596; PMID:\u00a036473629.","DOI":"10.1016\/j.phrs.2022.106596"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Surma S, Okopie\u0144 B, Murphy AJ, Banach M. High salt intake and atherosclerosis progression \u2013 not only via blood pressure: a narrative review. Nutrients 2025;17:3464. https:\/\/doi.org\/10.3390\/nu17213464; PMID:\u00a041228536.","DOI":"10.3390\/nu17213464"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Koutentakis M, Surma S, Rogula S, et al. The effect of a vegan diet on the cardiovascular system. J Cardiovasc Dev Dis 2023;10:94. https:\/\/doi.org\/10.3390\/jcdd10030094; PMID:\u00a036975858.","DOI":"10.3390\/jcdd10030094"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Surma S, Sahebkar A, Banach M, endorsed by the International Lipid Expert Panel (ILEP). Low carbohydrate\/ketogenic diet in the optimization of lipoprotein(a) levels: do we have sufficient evidence for any recommendation? Eur Heart J 2023;44:4904\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehad635; PMID:\u00a037769437.","DOI":"10.1093\/eurheartj\/ehad635"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Banach M, Lewek J, Surma S, et al. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. Eur J Prev Cardiol 2023;30:1975\u201385. https:\/\/doi.org\/10.1093\/eurjpc\/zwad229; PMID:\u00a037555441.","DOI":"10.1093\/eurjpc\/zwad229"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Masmoum MD, Khan S, Usmani WA, et al. The effectiveness of exercise in reducing cardiovascular risk factors among adults: a systematic review and meta-analysis. Cureus 2024;16:e68928. https:\/\/doi.org\/10.7759\/cureus.68928; PMID:\u00a039381478.","DOI":"10.7759\/cureus.68928"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Osadnik T, Go\u0142awski M, Lewandowski P, et al. A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. Pharmacol Res 2022;183:106402. https:\/\/doi.org\/10.1016\/j.phrs.2022.106402; PMID:\u00a035988871.","DOI":"10.1016\/j.phrs.2022.106402"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Damschroder LJ, Lutes LD, Kirsh S, et al. Small-changes obesity treatment among veterans: 12-month outcomes. Am J Prev Med 2014;47:541\u201353. https:\/\/doi.org\/10.1016\/j.amepre.2014.06.016; PMID:\u00a025217098.","DOI":"10.1016\/j.amepre.2014.06.016"},{"key":"ref64","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144; PMID:\u00a028444290."},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Lee J, Kang MW, Oh JI, et al. Association between delayed statin initiation after high LDL-cholesterol detection and cardiovascular risk in general health screening examinees. Eur Heart J Qual Care Clin Outcomes 2025;11:1377\u201387. https:\/\/doi.org\/10.1093\/ehjqcco\/qcaf105; PMID:\u00a040929091.","DOI":"10.1093\/ehjqcco\/qcaf105"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Ray KK, Ference BA, S\u00e9verin T, et al. World Heart Federation cholesterol roadmap 2022. Glob Heart 2022;17:75. https:\/\/doi.org\/10.5334\/gh.1154; PMID:\u00a036382159.","DOI":"10.5334\/gh.1154"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5; PMID:\u00a021067804.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664; PMID:\u00a028304224.","DOI":"10.1056\/NEJMoa1615664"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Bandyopadhyay D, Qureshi A, Ghosh S, et al. Safety and efficacy of extremely low LDL-cholesterol levels and its prospects in hyperlipidemia management. J Lipids 2018;2018:8598054. https:\/\/doi.org\/10.1155\/2018\/8598054; PMID:\u00a029850255.","DOI":"10.1155\/2018\/8598054"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 \u00d7 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015;65:1552\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2015.02.020; PMID:\u00a025770315.","DOI":"10.1016\/j.jacc.2015.02.020"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Patti G, Cumitini L, Bosco M, et al. Impact of a personalized, strike early and strong lipid-lowering approach on low-density lipoprotein-cholesterol levels and cardiovascular outcome in patients with acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother 2025;11:143\u201354. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf004; PMID:\u00a039855642.","DOI":"10.1093\/ehjcvp\/pvaf004"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Wang N, Woodward M, Huffman MD, Rodgers A. Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2022;15:e008552. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.121.008552; PMID:\u00a035430872.","DOI":"10.1161\/CIRCOUTCOMES.121.008552"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Mazhar F, Hjemdahl P, Clase CM, et al. Intensity of and adherence to lipid-lowering therapy as predictors of major adverse cardiovascular outcomes in patients with coronary heart disease. J Am Heart Assoc 2022;11:e025813. https:\/\/doi.org\/10.1161\/JAHA.122.025813; PMID:\u00a035861825.","DOI":"10.1161\/JAHA.122.025813"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Banach M, Surma S, Toth PP, endorsed by the International Lipid Expert Panel (ILEP). 2023: The year in cardiovascular disease \u2013 the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? Arch Med Sci 2023;19:1602\u201315. https:\/\/doi.org\/10.5114\/aoms\/174743; PMID:\u00a038058712.","DOI":"10.5114\/aoms\/174743"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Leosdottir M, Schubert J, Brandts J, et al. Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry. J Am Coll Cardiol 2025;85:1550\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2025.02.007; PMID:\u00a040240093.","DOI":"10.1016\/j.jacc.2025.02.007"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Ray KK, Kronenberg F. Seventeen years to change practice: will the 2025 ESC\/EAS dyslipidaemia guidelines finally break the Sisyphean cycle? Atherosclerosis 2026;413:120636. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120636; PMID:\u00a041564539.","DOI":"10.1016\/j.atherosclerosis.2026.120636"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Samnaliev M, Khan I, Potukuchi P, et al. Treatment adherence, persistence, and effectiveness of fixed dose combination versus free combination therapy of rosuvastatin-ezetimibe as a lipid-lowering therapy. Front Cardiovasc Med 2025;12:1461416. https:\/\/doi.org\/10.3389\/fcvm.2025.1461416; PMID:\u00a040454236.","DOI":"10.3389\/fcvm.2025.1461416"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Banach M, Surma S, Reiner Z, et al. Personalized management of dyslipidemias in patients with diabetes \u2013 it is time for a new approach (2022). Cardiovasc Diabetol 2022;21:263. https:\/\/doi.org\/10.1186\/s12933-022-01684-5; PMID:\u00a036443827.","DOI":"10.1186\/s12933-022-01684-5"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Banach M, Surma S, Kap\u0142on-Cie\u015blicka A, et al. Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association. Arch Med Sci 2023;20:28\u201342. https:\/\/doi.org\/10.5114\/aoms\/175879; PMID:\u00a038414478.","DOI":"10.5114\/aoms\/175879"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2017;2:370\u201380. https:\/\/doi.org\/10.1001\/jamacardio.2016.4828; PMID:\u00a028030716.","DOI":"10.1001\/jamacardio.2016.4828"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Jang Y, Kim BJ, Jeong YW, et al. Fenofibrate plus statin and ASCVD risk by triglyceride-rich lipoprotein cholesterol in 70,000 patients. J Lipid Res 2026;67:101024. https:\/\/doi.org\/10.1016\/j.jlr.2026.101024; PMID:\u00a041881263.","DOI":"10.1016\/j.jlr.2026.101024"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Kim NH, Kim JY, Choi J, Kim SG. Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study. Eur Heart J Cardiovasc Pharmacother 2024;10:118\u201327. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad090; PMID:\u00a038017618.","DOI":"10.1093\/ehjcvp\/pvad090"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine \u03a9-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation 2021;144:1981\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055654; PMID:\u00a034612056.","DOI":"10.1161\/CIRCULATIONAHA.121.055654"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Abidor E, Achkar M, Al Saidi I, et al. Comprehensive review of lipid management in chronic kidney disease and hemodialysis patients: conventional approaches, and challenges for cardiovascular risk reduction. J Clin Med 2025;14:643. https:\/\/doi.org\/10.3390\/jcm14020643; PMID:\u00a039860649.","DOI":"10.3390\/jcm14020643"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015;3:181\u201390. https:\/\/doi.org\/10.1016\/S2213-8587(14)70246-3; PMID:\u00a025660356.","DOI":"10.1016\/S2213-8587(14)70246-3"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Spitz J, Patel J, Agarwala A, et al. A critical appraisal of lipid management in the post-statin era: comparison on guidelines, therapeutic targets, and screening in a case-based framework of lipid management. JACC Adv 2025;4:101823. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101823; PMID:\u00a040579058.","DOI":"10.1016\/j.jacadv.2025.101823"},{"key":"ref87","unstructured":"Xie S, Galimberti F, Olmastroni E, et al. Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials. Cardiovasc Res 2024;120:333\u201344. https:\/\/doi.org\/10.1093\/cvr\/cvae034; PMID:\u00a038373008."},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Thompson W, Jeong I, Basque S, et al. Cholesterol levels and cardiovascular outcomes following statin initiation for primary prevention: a cohort study. JACC Adv 2025;4:101864. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101864; PMID:\u00a040713148.","DOI":"10.1016\/j.jacadv.2025.101864"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Mancia G, Facchetti R, Bombelli M, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005;45:1072\u20137. https:\/\/doi.org\/10.1161\/01.HYP.0000165672.69176.ed; PMID:\u00a015867138.","DOI":"10.1161\/01.HYP.0000165672.69176.ed"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Surma S, Sahebkar A, Banach M. Whether and why do we need a vaccine against atherosclerosis? Can we expect it anytime soon? Curr Atheroscler Rep 2024;26:59\u201371. https:\/\/doi.org\/10.1007\/s11883-023-01186-z; PMID:\u00a038165521.","DOI":"10.1007\/s11883-023-01186-z"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Lan NSR, Chen RT, Dwivedi G, et al. Learnings from implementation strategies to improve lipid management. Curr Cardiol Rep 2025;27:9. https:\/\/doi.org\/10.1007\/s11886-024-02174-8; PMID:\u00a039775142.","DOI":"10.1007\/s11886-024-02174-8"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Vatri M, Faggiano A, Angelino E, et al. Therapeutic inertia in lipid-lowering treatment: a narrative review. J Clin Med 2026;15:1075. https:\/\/doi.org\/10.3390\/jcm15031075; PMID:\u00a041682756.","DOI":"10.3390\/jcm15031075"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Wuttikul C, Kaew-umpa P, Kosumphant A, et al. Treatment initiation and modification among patients diagnosed with dyslipidemia: prevalence and associated factors. J Lipid Atheroscler 2026;15:286\u201396. https:\/\/doi.org\/10.12997\/jla.2026.15.2.286; PMID: 42211147.","DOI":"10.12997\/jla.2026.15.2.286"}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:20:56Z","timestamp":1783534856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":94,"URL":"https:\/\/doi.org\/10.15420\/ecr.2026.08","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"e37"}}